| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f7f2b4e5865e08c4b8590d51cd56145 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6823 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44 |
| filingDate |
1986-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38dd6085da304fae43f938650a857f25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39ccd5b65224d3be10b4daace75f80ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf6e2761dc5ff12c71202888fa975814 |
| publicationDate |
1987-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-8703286-A1 |
| titleOfInvention |
Ricin-antibody conjugates |
| abstract |
A conjugate of ricin being whole ricin or a derivative of ricin, which derivative per se being inhibitory of protein synthesis in cell free systems, with an antibody which is preferentially absorbed by a tumour cell as compared to a non-tumour cell and wherein the galactose binding site of said ricin is blocked and pharmacologically acceptable salts thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0327169-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5395924-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5635384-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0327169-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5248606-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9014844-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9014844-A3 |
| priorityDate |
1985-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |